Aquestive Therapeutics (AQST) vs CytomX Therapeutics (CTMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aquestive Therapeutics (AQST) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 23.2% versus a loss of 26.7%. Over five years, AQST leads with a +23.0% price change compared with -51.9% for CTMX. Aquestive Therapeutics is the larger company by market cap ($599.9 million vs $560.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | CTMX |
|---|---|---|
| Share price | $4.78 | $2.57 |
| Market cap | $599.95M | $560.00M |
| 1-day change | +0.42% | +4.05% |
| YTD return | -26.32% | -42.02% |
| 1-year return | -23.23% | -26.71% |
| 5-year return | +23.00% | -51.95% |
| EPS (TTM) | $-0.66 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $8.21 |
| 52-week low | $2.93 | $2.43 |
| Distance from 52-week high | -36.69% | -68.70% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +95.19% | +376.65% |
| Average volume | 2.68M | 3.38M |
| Shares outstanding | 125.51M | 217.90M |
| Employees | 147 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
AQST vs CTMX FAQ
Which is bigger, Aquestive Therapeutics or CytomX Therapeutics?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $599.95M compared with $560.00M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, AQST or CTMX?
AQST returned -23.23% over the past 12 months, compared with -26.71% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and CytomX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.